Negative pressure wound therapy vs usual care
Adverse events · people with leg ulcers undergoing a punch skin‐graft
1 finding from 1 review
- no estimate extracted0 studies · 1 participantsGRADE not reported
Findings
What do systematic reviews say?
891 questions · 902 findings · 317 reviews
No studies found 210 · 23.3%GRADE not reported 56 · 6.2%Very low 236 · 26.2%Low 220 · 24.4%Moderate 146 · 16.2%High 34 · 3.8%
Bevacizumab plus chemotherapy vs chemotherapy alone
Specific adverse events: gastrointestinal perforations or fistulae · women with persistent, recurrent, or metastatic cervical cancer
Bevacizumab plus chemotherapy probably leads to higher specificadverse events: gastrointestinal perforations or fistulae compared with chemotherapy (moderate certainty).
1 finding from 1 review
- Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer 2021 · Cochrane Headline outcomes onlyRR 18 [2.42, 133.67]1 study · 440 participantsModerate
Steroid therapy in first episode of nephrotic syndrome: 3 months or more vs 2 months of therapy
Adverse events: hypertension · children with nephrotic syndrome
Steroid therapy in first episode of nephrotic syndrome: 3 months or… showed no clear difference in adverse events: hypertension compared with 2 months of therapy (moderate certainty).
1 finding from 1 review
- RR 1.78 [0.55, 5.73]7 studies · 548 participantsModerate
Oral and sublingual immunotherapy vs no therapy
Number of children with mild‐to‐severe adverse events · children with egg allergy
Oral and sublingual immunotherapy may leads to higher number of children with mild‐to‐severe adverse events compared with no therapy (low certainty).
1 finding from 1 review
- RR 8.35 [5.31, 13.12]10 studies · 439 participantsLow
Massage vs usual care
Adverse events · people with postburn pruritus
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Extracorporeal shockwave therapy vs control
Adverse events · adolescents and adults with acute fractures in tibia and femur
The review found no eligible studies for this question.
1 finding from 1 review
- Ultrasound and shockwave therapy for acute fractures in adults 2023 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
tDCS plus speech and language therapy (SLT) vs sham tDCS plus SLT
tDCS plus speech and language therapy (SLT) versus sham tDCS plus SLT for improving aphasia: dropouts Dropouts and adverse events · patients with improving aphasia in patients with aphasia after stroke
1 finding from 1 review
- Transcranial direct current stimulation (tDCS) for improving aphasia in adults with aphasia after stroke 2019 · Cochrane Headline outcomes onlyno estimate extracted15 studies · 345 participantsLow
Biological therapy vs placebo, best supportive care (BSC) or no treatment
Serious adverse events · advanced gastric and oesophago‐gastric junction adenocarcinoma
Biological therapy showed no clear difference in serious adverse events compared with placebo, best supportive care (BSC) or no treatment (low certainty).
1 finding from 1 review
- Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma 2020 · Cochrane Headline outcomes onlyRR 1.14 [0.95, 1.37]2 studies · 638 participantsLow
Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs adjuvant immunotherapy (combined ipilimumab and nivolumab)
Adverse events, · stage III cutaneous melanoma
Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) showed no clear difference in adverse events, compared with adjuvant immunotherapy (combined ipilimumab and nivolumab) (low certainty).
1 finding from 1 review
- Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes onlyRR 1 [0.75, 1.34]1 study · 20 participantsLow
Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (nivolumab)
Adverse events, · stage III and IV cutaneous melanoma
It is very uncertain whether neoadjuvant immunotherapy (combined ipilimumab and nivolumab) changes adverse events, compared with neoadjuvant immunotherapy (nivolumab) (very low certainty).
1 finding from 1 review
- Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes onlyRR 8.73 [1.29, 59]1 study · 23 participantsVery low
Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (sequential treatment with ipilimumab then nivolumab)
Adverse events, · stage III cutaneous melanoma
1 finding from 1 review
- Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes onlyno estimate extracted1 study · 86 participantsLow
Biofeedback plus standard therapy vs usual care
Adverse events (AE) · people with irritable bowel syndrome
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Biofeedback plus standard therapy vs sham biofeedback plus standard therapy
Adverse events (AE) · people with irritable bowel syndrome
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Low‐level laser therapy vs Placebo (sham) laser therapy
Adverse events · Patients of any age in any setting requiring intervention for iatrogenic injury to the inferior alveolar or lingual nerve
The review found no eligible studies for this question.
1 finding from 1 review
- Interventions for iatrogenic inferior alveolar and lingual nerve injury 2014 · Cochrane All outcomesSoF row 'Adverse events': This outcome was not reported in the included studies.0 studiesNo studies found
Chemotherapy with TKI vs chemotherapy alone
Adverse events (grade ≥ 3) · recurrent platinum‐resistant EOC
Chemotherapy with TKI may leads to higher any adverse events (grade ≥3) compared with chemotherapy alone (low certainty).
1 finding from 1 review
- Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes onlyRR 1.23 [1.02, 1.49]4 studies · 548 participantsLow
Low‐level laser therapy and a splint vs ultrasound and a splint
Adverse events · carpal tunnel syndrome
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Low‐level laser therapy and a splint vs placebo and a splint
Adverse events · carpal tunnel syndrome
It is very uncertain whether low‐level laser therapy and a splint changes adverse events compared with placebo and a splint (very low certainty).
1 finding from 1 review
- RR 2 [0.38, 10.48]1 study · 112 participantsVery low
Hysterectomy (simple or radical) with neoadjuvant chemotherapy vs Radiotherapy alone
Severe adverse events and toxicity · women with locally advanced cervical cancer
Hysterectomy (simple or radical) with neoadjuvant chemotherapy showed no clear difference in severe adverse events and toxicity compared with radiotherapy alone (low certainty).
1 finding from 1 review
- Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer 2022 · Cochrane Headline outcomes onlyRR 1.32 [0.47, 3.71]1 study · 118 participantsLow
Apatinib plus chemotherapy or chemotherapy/brachytherapy vs chemotherapy or chemotherapy/brachytherapy
Adverse events: hypertension · women with recurrent or FIGO stage IVB cervical cancer
Apatinib plus chemotherapy or chemotherapy/brachytherapy may leads to higher specific adverse events: hypertension compared with chemotherapy or chemotherapy/brachytherapy (low certainty).
1 finding from 1 review
- Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer 2021 · Cochrane Headline outcomes onlyRR 5.14 [1.28, 20.73]1 study · 52 participantsLow
Apatinib plus chemotherapy or chemotherapy/brachytherapy vs chemotherapy or chemotherapy/brachytherapy
Serious adverse events ‐ not reported · women with recurrent or FIGO stage IVB cervical cancer
The review found no eligible studies for this question.
1 finding from 1 review
- Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found